The three Reviscon presentations with their pre-filled syringes: Reviscon, Reviscon Plus and Reviscon Mono

Reviscon

Sodium hyaluronate intra-articular solution for viscosupplementation, supplied in three presentations: Reviscon, Reviscon Plus and Reviscon Mono. CE marked, Play Sure Doping Free certified.

Not to scale. Product shown enlarged for detail.

Reviscon pre-filled syringe
Reviscon Plus pre-filled syringe
Reviscon Mono pre-filled syringe
Indication & Usage

Osteoarthritis: viscosupplementation

Reviscon 1.0%, Reviscon Plus 1.6% and Reviscon Mono 2.0% are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, for example acetaminophen (paracetamol). Administered by intra-articular injection by a qualified physician.

01
Injection regimen

Reviscon: 3 to 5 injections, one week apart. Reviscon Plus: 1 to 3 injections. Reviscon Mono: a single injection, every six months.

02
Administration

Intra-articular injection by a qualified physician. Do not inject intravenously. Strict aseptic technique required.

03
Play Sure Doping Free certification

Reviscon is Play Sure Doping Free certified and contains no prohibited substances. Safe for use in competitive athletes subject to WADA testing. Confirm current WADA list at time of use.

Presentations

One hyaluronate, three presentations

Reviscon is supplied in three presentations that differ in injection regimen. Formulation, indication and doping-free certification are common to all three. Select by treatment protocol and patient profile.

Reviscon packaging
Weekly course
Reviscon

The reference presentation. A graduated weekly course for osteoarthritis of the knee.

Regimen3 to 5 injections, one week apart
Reviscon Plus packaging
Reduced course
Reviscon Plus

The same indication with fewer injections. For protocols and patients where visit count matters.

Regimen1 to 3 injections
Reviscon Mono packaging
Single injection
Reviscon Mono

A single injection, every six months. For patients where a weekly course is not practical.

RegimenSingle injection, every 6 months
Product Specifications

Technical specifications

Formulation data, regulatory classification, injection parameters, and handling requirements for Reviscon sodium hyaluronate. Values shown are for the standard Reviscon presentation.

HA Type
Sodium Hyaluronate: linear, non-cross-linked
Molecular Weight
approx. 3 MDa
Concentration
Reviscon: 10 mg/mL (20 mg / 1.0%)
Plus: 16 mg/mL (32 mg / 1.6%)
Mono: 20 mg/mL (48 mg / 2.0%)
Volume per Syringe
Reviscon and Plus: 2.0 mL
Mono: 2.4 mL
Injection Regimen
Reviscon: 3 to 5, weekly
Plus: 1 to 3, weekly
Mono: single injection, every 6 months
Presentation
Pre-filled syringe, ready to use
Expiry
Do not use after the date printed on the pack
Storage
2°C to 25°C, protect from light and shocks, do not freeze
Regulatory
CE Class III (MDD 93/42/EEC) · MDR 2017/745 transition in progress · ISO 13485:2016
Doping status
Play Sure Doping Free certified
Sterility
Sterile, single-use only
ISO Standard
ISO 13485:2016
Mechanism of Action

How Reviscon works in the joint

In osteoarthritic joints, endogenous HA concentration falls and the average molecular weight decreases, reducing synovial fluid viscosity. The result is impaired joint lubrication, increased cartilage stress under load, and progressive pain. Reviscon restores the viscoelastic properties of the synovial fluid through direct supplementation with exogenous sodium hyaluronate.

01
LubricationHA molecules form a viscous layer between articular surfaces, reducing friction and protecting cartilage from mechanical wear during joint movement.
02
Shock absorptionThe elastic component of HA solution absorbs mechanical impulses during loading, distributing stress more evenly across the joint surface.
03
Biological responseEvidence suggests HA supplementation stimulates endogenous HA synthesis and has anti-inflammatory effects that extend the duration of pain relief beyond the HA half-life.
HA Biomaterial Science
FEMUR FIBULA TIBIA MENISCUS CARTILAGE SYNOVIAL FLUID + REVISCON HA Coronal section, left knee. Schematic, not to scale.
Clinical Evidence

Published outcomes: Reviscon

For healthcare professionals. Always refer to the current instructions for use (IFU) before clinical use.

42%
Reduction in WOMAC total index at 6 months

Prospective study of the Reviscon sodium hyaluronate portfolio (Reviscon, Plus and Mono) in knee osteoarthritis. Overall WOMAC scores for pain, stiffness and physical function fell by an average of 42% across all patient groups over six months.

Dıraçoğlu D et al. · Istanbul University Faculty of Medicine
35%
Reduction in VAS pain and quality-of-life scores at 6 months

In the same portfolio study, overall VAS scores for rest pain, movement pain and quality of life fell by an average of 35% across all patient groups over six months. Reviscon is clinically proven and effective up to six months.

Dıraçoğlu D et al. · Istanbul University Faculty of Medicine
Safety
Well-tolerated in intra-articular use

Intra-articular viscosupplementation with Reviscon is a safe, well-tolerated procedure for patients with osteoarthritis who have not responded sufficiently to prior pharmacologic treatment. Report suspected side effects to the VSY Biotechnology Quality team at complaint@vsybiotechnology.com.

Data on file · VSY Biotechnology GmbH
View All Orthopedics Evidence